EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies

Jyoti Sutar iD, Priyanka Jayal, Ranajoy Mullick iD, Sangeeta Chaudhary, Prajakta Kamble, Shilpa Bhowmick, Snehal Kaginkar, Varsha Padwal, Pratik Devadiga, Namrata Neman, Dale Kitchin, Haajira Kaldine und 39 weitere

Journal of Virology · 2025

DOI: 10.1128/jvi.00008-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Jyoti Sutar und 50 weiteren Autor:innen. Beteiligte Einrichtung: Antibody Translational Research Program, Center for Virus Research, Vaccines & Therapeutics, BRIC-Translational Health Science & Technology Institute…. Hauptthemen laut MEDLINE: HIV-1, HIV Antibodies, HIV Infections, Antibodies, Neutralizing. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, DBT-Wellcome Trust India Alliance, Wellcome Trust DBT India Alliance (India Alliance).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While broadly neutralizing antibodies (bnAbs) have been clinically shown to prevent HIV-1 acquisition, their relative effectiveness against regionally relevant HIV-1 forms is not clear. In the present study, we examined the extent of neutralization susceptibility of contemporary HIV-1 Indian clade C at a population level along with a head-to-head comparison with that from South Africa against a panel of clinically relevant best-in-class bnAbs. Env-pseudotyped viruses encoding HIV-1 India clade C env were found to be best neutralized by the V3 glycan-directed bnAbs (10-1074 and BG18) and select CD4 binding site (CD4bs)-directed bnAbs (VRC07, N6, and 1-18); however, they demonstrated significant resistance to V1/V2 apex-directed bnAbs. Interestingly, the magnitude of the neutralization sensitivity differed between contemporary India and South Africa clade C. Neutralization resistance to key bnAbs was observed to be associated with differences in residues on Env that form bnAb contact sites, gp120 loop lengths, and potential N-linked glycans. Notably, the second generation CD4bs bnAbs (VRC07, N6, 1-18) showed neutralization of VRC01- and 3BNC117-resistant viruses but with two- to sevenfold reduced potency compared to the VRC01-sensitive counterparts, likely due to the enrichment of resistance-associated residues observed in loop D. Predictive analysis indicated that the combination of BG18, N6, and PGDM1400 can provide over 95% neutralization coverage of contemporary India clade C at 1 µg/mL (IC80), an observation distinct from that observed with Africa clade C. Our study clearly highlights that both the complementarity of bnAb classes and the regionally relevant HIV-1 forms are important in achieving clinical effectiveness. IMPORTANCE While the development of vaccines to prevent HIV infection remains a global priority, their potential effectiveness is limited by the extraordinarily diversified circulating forms of HIV-1. The prospect of best-in-class broadly neutralizing antibodies (bnAbs) as a potential prevention option has been demonstrated in several studies, including the phase 2b Antibody-Mediated Prevention trials; however, to be broadly applicable, bnAbs will need to overcome the substantial variability of HIV env circulating globally, beyond the regions where efficacy trials are conducted. The present study highlights that the region-specific contemporary HIV-1 clade C viruses not only vary in their degree of susceptibility to the best-in-class clinically relevant bnAbs, but also are evolving at a population level to become increasingly resistant to the best-in-class bnAbs. Overall, the outcome of this study highlights the need for periodic assessment of sequence and neutralization profiles of the circulating regionally relevant HIV-1 forms toward prioritizing the bnAb combination suitable for effective intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV AntibodiesHIV InfectionsAntibodies, NeutralizingBroadly Neutralizing AntibodiesHumansSouth AfricaNeutralization TestsHIV Envelope Protein gp120Indiaenv Gene Products, Human Immunodeficiency VirusEpitopesCD4 Antigens

Stichwörter der Autor:innen

HIV-1IndiaSouth AfricabnAbclade Ccontemporary virusenvelopegenetic diversityneutralizing antibodiesprevention

Substanzen

HIV AntibodiesAntibodies, NeutralizingHIV Envelope Protein gp120Broadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesCD4 Antigens

Autor:innen und Institutionen

  • Antibody Translational Research Program, Center for Virus Research, Vaccines & Therapeutics, BRIC-Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
  • IAVI, Gurugram, Haryana, India.
  • IAVI, New York, New York, USA.
  • Molecular and Translational Virology Unit, Center for Virus Research, Vaccines & Therapeutics, BRIC-Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
  • ICMR- National Institute of Research in Reproductive & Child Health, Mumbai, Maharashtra, India.
  • Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Jyoti Sutar, Ranajoy Mullick, Suprit Deshpande, Penny L Moore, Jayanta Bhattacharya

Förderung

  • Wellcome Trust
  • DBT-Wellcome Trust India Alliance
  • Wellcome Trust DBT India Alliance (India Alliance)
  • Department of Biotechnology, Ministry of Science and Technology, India
  • International AIDS Vaccine Initiative

Zitieren

APA

Sutar, J., Jayal, P., Mullick, R., Chaudhary, S., Kamble, P., Bhowmick, S., Kaginkar, S., Padwal, V., Devadiga, P., Neman, N., Kitchin, D., Kaldine, H., Mkhize, N. N., Ndlovu, B., Gounder, K., Mukherjee, S., Shrivas, S., Sharma, N., Prasad, C., …, & Bhattacharya, J. (2025). Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies. Journal of Virology. https://doi.org/10.1128/jvi.00008-25

Vancouver

Sutar J, Jayal P, Mullick R, Chaudhary S, Kamble P, Bhowmick S, et al. Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies. Journal of Virology. 2025. doi:10.1128/jvi.00008-25

BibTeX
@article{Sutar2025,
  author = {Sutar, Jyoti and Jayal, Priyanka and Mullick, Ranajoy and Chaudhary, Sangeeta and Kamble, Prajakta and Bhowmick, Shilpa and Kaginkar, Snehal and Padwal, Varsha and Devadiga, Pratik and Neman, Namrata and Kitchin, Dale and Kaldine, Haajira and Mkhize, Nonhlanhla N and Ndlovu, Bongiwe and Gounder, Kamini and Mukherjee, Sohini and Shrivas, Shweta and Sharma, Neha and Prasad, Chaman and Tewatia, Sonia and Parihar, Nainika and Kumar, Naresh and Kasarpalkar, Nandini and Singh, Balwant and Mohapatra, Shobha and Aquil, Mohammad and Kumar, C Vishal and Dinesha, Thongadi Ramesh and Srikrishnan, Aylur Kailasom and Shastri, Jayanthi and Agrawal, Sachee and Gaikwad, Sushma and Mondal, Sayantani and Bandyopadhyay, Bhaswati and Guha, Subhasish Kamal and Kale, Dipesh and Biswas, Debasis and Patil, Dhanashree and Paranjape, Ramesh S and Mukhopadhyay, Satyajit and Hema and Das, Ritika and Kondapi, Anand and Bhor, Vikrant and Deshpande, Suprit and Sok, Devin and Ndung'u, Thumbi and Moore, Penny L and Murugavel, Kailapuri Gangatharan and Patel, Vainav and Bhattacharya, Jayanta},
  title = {Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.00008-25}
}
Kostenlos starten →